• AEBSF.HCl in Protease and Necroptosis Assays

  2026-09-09

  AEBSF.HCl provides irreversible, broad-spectrum serine protease inhibition for cell lysates, amyloid precursor protein studies, and leukemic-cell lysis assays. Its most valuable role in necroptosis experiments is as an orthogonal serine-protease probe—not a substitute for cathepsin B inhibition—helping researchers separate protease classes during lysosomal membrane permeabilization studies.

• Anti-b, mTOR Signaling, and Hepatic Steatosis

  2026-09-08

  The reference study shows that Anti-b reduces diet- and oleic acid-induced dyslipidaemia and hepatic lipid accumulation in animal and cellular models. Its central mechanistic contribution is the linking of Anti-b-associated mTOR engagement with reduced mTOR phosphorylation and downstream suppression of PPARγ and SREBP1 signalling.

• CCT007093: A Practical PPM1D Inhibitor Workflow

  2026-09-08

  CCT007093 enables mechanism-focused studies of PPM1D/WIP1, P38 kinase activation, and stress-linked cytotoxicity. This workflow connects biochemical inhibition with breast cancer and renal injury assays while emphasizing DMSO handling, temporal controls, and orthogonal validation.

• Birinapant (TL32711) in Apoptosis Research

  2026-09-07

  Birinapant (TL32711) is a bivalent SMAC mimetic IAP antagonist that targets cIAP1, cIAP2, XIAP, and ML-IAP. Its reported mechanism links IAP antagonism to TNF-mediated NF-κB inhibition, caspase-8 activation, TRAIL potency enhancement, and apoptosis induction in cancer cells, while MDM1 evidence provides a separate biomarker framework for colorectal cancer chemoradiotherapy.

• FH1 Small Molecule for Hepatocyte Maturation

  2026-09-07

  FH1 is a small molecule for cultured hepatocyte function enhancement during iPS cell differentiation to hepatocytes. Product information reports approximately 2-fold higher albumin secretion, larger hepatocyte-like cell colonies, increased CYP3A4, and reduced AFP under the described differentiation context.

• Cefotaxime Workflows for Resistance Research

  2026-09-05

  Cefotaxime connects beta-lactam activity, resistance phenotyping, and controlled bacterial infection models without treating one susceptibility result as a complete mechanism. This practical guide shows how to build reproducible assays, interpret plasmid-associated resistance, and troubleshoot stability or genotype–phenotype discordance.

• Metoprolol Tartrate: Selectivity as a Translational Tool

  2026-09-04

  Metoprolol Tartrate is more than a cardioselective beta blocker for cardiac assays: it is a useful mechanistic control for separating β1-dependent cardiovascular biology from β2/β3-linked hematopoietic regeneration. This article translates receptor selectivity into practical study-design guidance for cardiovascular research, hypertension research, and transplant-adjacent models.

• Sulfo-NHS-SS-Biotin for Surface Proteomics

  2026-09-04

  Sulfo-NHS-SS-Biotin combines water-soluble amine reactivity with a cleavable disulfide linker, enabling selective live-cell surface labeling and controlled affinity release. Its workflow flexibility supports protein purification, interaction mapping, and assays inspired by emerging cell-surface glycoRNA–RBP biology.

• Gemcitabine as a Mechanistic Probe in Cancer Research

  2026-09-03

  A translational framework for using Gemcitabine to connect DNA replication stress, checkpoint signaling, apoptosis, and cancer stem cell biology. The article integrates the TAK1–YAP gastric cancer stem cell study with practical assay design and strategic guidance for preclinical researchers.

• Niclosamide Workflows for STAT3 Cancer Research

  2026-09-03

  Build reproducible Niclosamide experiments around STAT3 Tyr-705 phosphorylation, apoptosis, and cell-cycle readouts rather than relying on viability alone. A genotype-aware strategy inspired by ATRX-deficient glioma research helps extend this small-molecule workflow into better controlled cancer models without overstating the evidence.

• Mianserin HCl: From 5-HT2 Biology to Translation

  2026-09-02

  A translational perspective on Mianserin HCl as a 5-HT2 receptor antagonist, integrating receptor pharmacology, historical clinical evidence, assay design, cyclodextrin chemistry, and exploratory antipathogenic research.

• ER Stress, GRP78/ATF6/CHOP, and Intestinal Stem Cells

  2026-09-02

  The reference study shows that tunicamycin-induced endoplasmic reticulum stress damages the small-intestinal mucosa by reducing intestinal stem-cell abundance and differentiation capacity while increasing crypt apoptosis. Its central contribution is the mechanistic association of these effects with GRP78/ATF6/CHOP activation and suppression of p44/42 MAPK signaling, providing a framework for separating stem-cell loss from broader epithelial injury.

• SB-505124 Hydrochloride: Assay Workflows

  2026-09-01

  Build more interpretable TGF-β pathway assays with SB-505124 hydrochloride, from Smad2/3 phosphorylation checks to fibroblast activation and tissue-remodeling models. The workflow also shows how to connect pathway inhibition with cancer-cell mechanics without confusing ALK signaling effects with direct BK-channel modulation.

• Ceftolozane/Tazobactam: Mechanism, PK, and Resistance

  2026-09-01

  The reference review presents ceftolozane/tazobactam as an integrated strategy against resistant Gram-negative pathogens, combining potent cephalosporin activity with β-lactamase inhibition. Its analysis connects PBP binding, susceptibility patterns, pharmacokinetics, pharmacodynamics, clinical dosing, and safety, providing a useful framework for designing antibacterial studies.

• Torin2: A Selective mTOR Inhibitor Guide

  2026-08-31

  Torin2 is a potent, selective mTOR inhibitor for mechanistic cancer research. Its reported activity in medullary thyroid carcinoma models and animal tumor studies supports pathway-focused experiments, while recent RNA Pol II research clarifies why apoptosis should not automatically be attributed to transcriptional loss.

8731 records 4/583 page Previous Next 12345 下5页 Last page